United Kingdom

People: BioXcel Therapeutics Inc (BTAI.OQ)

BTAI.OQ on NASDAQ Stock Exchange Capital Market

9:00pm BST
Change (% chg)

$0.11 (+1.00%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Risinger, Robert 

Mr. Robert Risinger is Vice President Clinical Development of the company. He joins BTI with more than 10 years of neuropsychiatric drug development experience at companies including Alkermes, Bristol-Myers Squibb, Johnson & Johnson and most recently NeuroRx Pharmaceuticals. Prior to his industry career, Dr. Risinger was an Assistant Professor of Psychiatry and Behavioral Medicine at Medical College of Wisconsin. He also served as a Major and Staff Psychiatrist in the U.S. Air Force. He holds an MD from the University of Pittsburgh School of Medicine and completed his Psychiatric Residency at Emory University School of Medicine. The hiring of Dr. Risinger brings BioXcel Therapeutics' total employees to nearly 20.

Basic Compensation

Total Annual Compensation, --
Restricted Stock Award, --
Long-Term Incentive Plans, --
All Other, --
Fiscal Year Total, --

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --